ECSP22083926A - Compuestos útiles para inhibir la quinasa ret - Google Patents
Compuestos útiles para inhibir la quinasa retInfo
- Publication number
- ECSP22083926A ECSP22083926A ECSENADI202283926A ECDI202283926A ECSP22083926A EC SP22083926 A ECSP22083926 A EC SP22083926A EC SENADI202283926 A ECSENADI202283926 A EC SENADI202283926A EC DI202283926 A ECDI202283926 A EC DI202283926A EC SP22083926 A ECSP22083926 A EC SP22083926A
- Authority
- EC
- Ecuador
- Prior art keywords
- ret kinase
- compounds useful
- inhibiting ret
- ret
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se proporcionan inhibidores de la quinasa RET de acuerdo con la fórmula (I): sales aceptables desde el punto de vista farmacéutico de estos, composiciones farmacéuticas de estos y métodos para su uso en el tratamiento de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidas enfermedades y trastornos asociados a RET. A, R1, n, X1, X2, X3, X4, y R2 tienen los significados dados en la memoria descriptiva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063015933P | 2020-04-27 | 2020-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22083926A true ECSP22083926A (es) | 2022-11-30 |
Family
ID=75914595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202283926A ECSP22083926A (es) | 2020-04-27 | 2022-10-27 | Compuestos útiles para inhibir la quinasa ret |
Country Status (18)
Country | Link |
---|---|
US (2) | US11613533B2 (es) |
EP (1) | EP4143184A1 (es) |
JP (1) | JP7441972B2 (es) |
KR (1) | KR20230005301A (es) |
CN (1) | CN115667253A (es) |
AR (1) | AR121914A1 (es) |
AU (1) | AU2021263541B2 (es) |
BR (1) | BR112022021735A2 (es) |
CA (1) | CA3177080A1 (es) |
CL (1) | CL2022003000A1 (es) |
CO (1) | CO2022016013A2 (es) |
DO (1) | DOP2022000234A (es) |
EC (1) | ECSP22083926A (es) |
IL (1) | IL297551B2 (es) |
MX (1) | MX2022013482A (es) |
PE (1) | PE20230780A1 (es) |
TW (1) | TWI777509B (es) |
WO (1) | WO2021222017A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20231984A1 (es) * | 2020-11-06 | 2023-12-12 | Lilly Co Eli | Derivados de pirazol como inhibidores de la ret-cinasa |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201524958A (zh) * | 2013-03-15 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | 用作轉染期間重排抑制劑之新穎化合物 |
WO2017145050A1 (en) * | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
US10183928B2 (en) * | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
WO2020035065A1 (zh) * | 2018-08-17 | 2020-02-20 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡唑衍生物 |
-
2021
- 2021-04-22 TW TW110114546A patent/TWI777509B/zh active
- 2021-04-22 AR ARP210101083A patent/AR121914A1/es unknown
- 2021-04-23 AU AU2021263541A patent/AU2021263541B2/en active Active
- 2021-04-23 EP EP21725633.8A patent/EP4143184A1/en active Pending
- 2021-04-23 MX MX2022013482A patent/MX2022013482A/es unknown
- 2021-04-23 WO PCT/US2021/028836 patent/WO2021222017A1/en active Application Filing
- 2021-04-23 JP JP2022565547A patent/JP7441972B2/ja active Active
- 2021-04-23 KR KR1020227041444A patent/KR20230005301A/ko active Search and Examination
- 2021-04-23 BR BR112022021735A patent/BR112022021735A2/pt unknown
- 2021-04-23 CA CA3177080A patent/CA3177080A1/en active Pending
- 2021-04-23 CN CN202180044981.8A patent/CN115667253A/zh active Pending
- 2021-04-23 US US17/238,370 patent/US11613533B2/en active Active
- 2021-04-23 PE PE2022002489A patent/PE20230780A1/es unknown
- 2021-04-23 IL IL297551A patent/IL297551B2/en unknown
-
2022
- 2022-10-27 EC ECSENADI202283926A patent/ECSP22083926A/es unknown
- 2022-10-27 CL CL2022003000A patent/CL2022003000A1/es unknown
- 2022-10-27 DO DO2022000234A patent/DOP2022000234A/es unknown
- 2022-11-09 CO CONC2022/0016013A patent/CO2022016013A2/es unknown
-
2023
- 2023-02-06 US US18/165,037 patent/US11964968B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DOP2022000234A (es) | 2022-11-30 |
AU2021263541A1 (en) | 2022-11-24 |
JP2023523315A (ja) | 2023-06-02 |
IL297551B2 (en) | 2024-06-01 |
BR112022021735A2 (pt) | 2022-12-06 |
EP4143184A1 (en) | 2023-03-08 |
IL297551B1 (en) | 2024-02-01 |
US11964968B2 (en) | 2024-04-23 |
CL2022003000A1 (es) | 2023-06-23 |
PE20230780A1 (es) | 2023-05-09 |
CA3177080A1 (en) | 2021-11-04 |
US20230312544A1 (en) | 2023-10-05 |
JP7441972B2 (ja) | 2024-03-01 |
CN115667253A (zh) | 2023-01-31 |
MX2022013482A (es) | 2022-11-16 |
WO2021222017A1 (en) | 2021-11-04 |
US11613533B2 (en) | 2023-03-28 |
AU2021263541B2 (en) | 2024-03-07 |
AR121914A1 (es) | 2022-07-20 |
TWI777509B (zh) | 2022-09-11 |
TW202206428A (zh) | 2022-02-16 |
US20210363140A1 (en) | 2021-11-25 |
IL297551A (en) | 2022-12-01 |
KR20230005301A (ko) | 2023-01-09 |
CO2022016013A2 (es) | 2022-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
CO2023008167A2 (es) | Inhibidores de prmt5 | |
CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
DOP2019000091A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
CR20190218A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
CO2023007504A2 (es) | Derivados de carboxamida tricíclica como inhibidores de prmt5 | |
CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
CO6290687A2 (es) | Inhibidores de cinasa pim y metodos para su uso | |
UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
BR112017017135A2 (pt) | inibidores de tgf-beta | |
AR063098A1 (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina | |
UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
AR085308A1 (es) | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea | |
ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
CL2022003812A1 (es) | Inhibidores de rip1k | |
AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
CO2024000565A2 (es) | Inhibidores del inflamasoma nlrp3 | |
ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
AR127561A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
CO2022000118A2 (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
ECSP23075535A (es) | Compuestos cíclicos y métodos de uso |